A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

Nancy J. Olsen; Raye H. Brooks; John J. Cush; Peter E. Lipsky; E. William St. Clair; Eric L. Matteson; Kenneth N. Gold; Grant W. Cannon; Christopher G. Jackson; W. Joseph McCune; David A. Fox; Grace Teal; James Gruber; Luis Espinoza; Jacques Caldwell; Micheal Weisman; Sicy Lee; Steven Abramson; Leonard Calabrese; Thomas Medsger; Betty Nelson; Todd Lorenz; Vibeke Strand

doi:10.1002/art.1780390705

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

Nancy J. Olsen
, Raye H. Brooks
, John J. Cush
, Peter E. Lipsky
, E. William St. Clair
, Eric L. Matteson
, Kenneth N. Gold
, Grant W. Cannon
, Christopher G. Jackson
, W. Joseph McCune
, David A. Fox
, Grace Teal
, James Gruber
, Luis Espinoza
, Jacques Caldwell
, Micheal Weisman
, Sicy Lee
, Steven Abramson
, Leonard Calabrese
, Thomas Medsger

Betty Nelson, Todd Lorenz, Vibeke Strand

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Abstract

Objective. To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double- blind, multiple-dose, placebo-controlled study of CD5-IC. Results. Treatment with CD5-IC in doses up to 8 mg/m²/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. Conclusion. At the doses used in this study, CD5-IC was ineffective for treating RA.

Original language	English (US)
Pages (from-to)	1102-1108
Number of pages	7
Journal	Arthritis and rheumatism
Volume	39
Issue number	7
DOIs	https://doi.org/10.1002/art.1780390705
State	Published - Jul 1996

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Rheumatology
Immunology
Pharmacology (medical)

Access to Document

10.1002/art.1780390705

Cite this

Olsen, N. J., Brooks, R. H., Cush, J. J., Lipsky, P. E., St. Clair, E. W., Matteson, E. L., Gold, K. N., Cannon, G. W., Jackson, C. G., McCune, W. J., Fox, D. A., Teal, G., Gruber, J., Espinoza, L., Caldwell, J., Weisman, M., Lee, S., Abramson, S., Calabrese, L., ... Strand, V. (1996). A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. Arthritis and rheumatism, 39(7), 1102-1108. https://doi.org/10.1002/art.1780390705

@article{5d082a7ea0284039828d61bf734890a2,

title = "A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis",

abstract = "Objective. To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double- blind, multiple-dose, placebo-controlled study of CD5-IC. Results. Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48\% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. Conclusion. At the doses used in this study, CD5-IC was ineffective for treating RA.",

author = "Olsen, \{Nancy J.\} and Brooks, \{Raye H.\} and Cush, \{John J.\} and Lipsky, \{Peter E.\} and \{St. Clair\}, \{E. William\} and Matteson, \{Eric L.\} and Gold, \{Kenneth N.\} and Cannon, \{Grant W.\} and Jackson, \{Christopher G.\} and McCune, \{W. Joseph\} and Fox, \{David A.\} and Grace Teal and James Gruber and Luis Espinoza and Jacques Caldwell and Micheal Weisman and Sicy Lee and Steven Abramson and Leonard Calabrese and Thomas Medsger and Betty Nelson and Todd Lorenz and Vibeke Strand",

year = "1996",

month = jul,

doi = "10.1002/art.1780390705",

language = "English (US)",

volume = "39",

pages = "1102--1108",

journal = "Arthritis and rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "7",

}

Olsen, NJ, Brooks, RH, Cush, JJ, Lipsky, PE, St. Clair, EW, Matteson, EL, Gold, KN, Cannon, GW, Jackson, CG, McCune, WJ, Fox, DA, Teal, G, Gruber, J, Espinoza, L, Caldwell, J, Weisman, M, Lee, S, Abramson, S, Calabrese, L, Medsger, T, Nelson, B, Lorenz, T & Strand, V 1996, 'A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis', Arthritis and rheumatism, vol. 39, no. 7, pp. 1102-1108. https://doi.org/10.1002/art.1780390705

TY - JOUR

T1 - A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

AU - Olsen, Nancy J.

AU - Brooks, Raye H.

AU - Cush, John J.

AU - Lipsky, Peter E.

AU - St. Clair, E. William

AU - Matteson, Eric L.

AU - Gold, Kenneth N.

AU - Cannon, Grant W.

AU - Jackson, Christopher G.

AU - McCune, W. Joseph

AU - Fox, David A.

AU - Teal, Grace

AU - Gruber, James

AU - Espinoza, Luis

AU - Caldwell, Jacques

AU - Weisman, Micheal

AU - Lee, Sicy

AU - Abramson, Steven

AU - Calabrese, Leonard

AU - Medsger, Thomas

AU - Nelson, Betty

AU - Lorenz, Todd

AU - Strand, Vibeke

PY - 1996/7

Y1 - 1996/7

N2 - Objective. To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double- blind, multiple-dose, placebo-controlled study of CD5-IC. Results. Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. Conclusion. At the doses used in this study, CD5-IC was ineffective for treating RA.

AB - Objective. To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). Methods. A total of 104 evaluable patients were enrolled in a multicenter, double- blind, multiple-dose, placebo-controlled study of CD5-IC. Results. Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. Conclusion. At the doses used in this study, CD5-IC was ineffective for treating RA.

UR - https://www.scopus.com/pages/publications/8944229691

UR - https://www.scopus.com/pages/publications/8944229691#tab=citedBy

U2 - 10.1002/art.1780390705

DO - 10.1002/art.1780390705

M3 - Article

C2 - 8670317

AN - SCOPUS:8944229691

SN - 0004-3591

VL - 39

SP - 1102

EP - 1108

JO - Arthritis and rheumatism

JF - Arthritis and rheumatism

IS - 7

ER -

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this